Skip to content

The Aesthetic Surgery Education and Research Foundation

Newsroom
Cosmetic Surgery Training in United States Plastic Surgery Residency Programs: An 8 Year Update Print

The ASERF Scientific Research Committee and Board of Directors are pleased to announce the following grant award:

Researcher: James Zins, MD

Grant Award: ASERF Interim Grant

Amount Awarded: $12,000

Project Name: Cosmetic Surgery Training in United States Plastic Surgery Residency Programs: An 8 Year Update 

Project Summary: In 2013, over $12 billion was spent on cosmetic procedures. The 11.4 million cosmetic procedures that were performed in 2013 alone represent an increase of over 1.3 million procedures from the previous year and capture the exponential rate at which cosmetic surgery continues to grow within the field of plastic surgery (ASAPS 2013, ASAPS 2012, Kenkel). The advances in technology, growth of non-invasive techniques, and an increasingly informed patient population have all created a deeply sophisticated sub- specialty of plastic surgery, offering both patients and surgeons a multitude of treatment options. However, restriction of work hours in residency and a wide diversity of case load make mastery of the entire field of plastic surgery difficult. The surest means of maintaining our preeminence in cosmetic surgery is to produce the best surgeon product. Therefore, attention to details of our plastic surgery training programs is of great importance.

Our research group has previously conducted two survey studies to gauge the perception of plastic surgery residents and program directors in regards to current cosmetic surgery training, once in 2006 (Morrison et al.) and once in 2009 (Oni et al.), and we hope to once again perform a survey of the topic within the context of changes and trends in plastic surgery over the past 5 years. Since the last survey in 2009, there have been a few changes in the field that should be taken into consideration: The growth of integrated plastic surgery residencies, the expansion of the independent residency from 2 to 3 years, the standardization of the plastic surgery curriculum, and the overwhelming growth of web-based learning tools and portable education modalities.

In our proposed survey we hope to assess, 1. The effect of independent vs. integrated plastic surgery training programs on residents and programs directors' opinions of cosmetic surgery training, 2. Assess the effect of web based training and mobile learning devices (smart phones, tablets) on perceptions of training, and finally 3. Assess the current state of affairs in terms of our core survey questions from the past regarding cosmetic education from both resident and program directors' opinions.

 
Adipose Derived Stromal Cell (ADSC) Injections Print

The ASERF Scientific Research Committee and Board of Directors are pleased to announce the following grant award:

Researcher: Peter Fodor, MD

Grant Award: ASERF Interim Grant

Amount Awarded: $50,000

Project Name: Adipose Derived Stromal Cell (ADSC) Injections 

Project Summary: Osteoarthritis (OA) of the knee results from degeneration of the cartilage in the knee and is the most common musculoskeletal disorder (Buckwalter and Martin, 2006).  Causes of OA include age, heredity, injury, excessive exercise, obesity, and disease, and occurrence is expected to increase exponentially as the world population ages and obesity increases (Dunlop et al., 2003).  At present treatment of OA may include medication to control pain, injection of corticosteroids to reduce inflammation, or injection of viscosupplements based on hyaluronic acid.  None of these treatment types reverse or repair the degenerative nature of the disease (Coleman, 2010).  Regenerative cell therapy uses the anti-inflammatory and healing properties of a patient’s own cells to treat inflamed and painful tissues.  Recent studies on animal and human subjects have shown the efficacy of adipose-derived stem and stromal vascular fraction cells to decrease inflammation and pain and to increase the range of motion in joints (Black et al., 2007; Davatchi et al., 2011; Koh et al., 2013; Orozco et al., 2013; Pak et al., 2013; Peeters et al., 2013; Wakitani et al., 2002).

Regenerative cells that may be derived from adipose tissue include the Stromal Vascular Fraction (SVF) cell which is a heterogeneous reparative cell population (Lin, 2009; Lindoos et al., 2010; Tholpady et al., 2006; Yoshimura et al., 2010).  The adipose-derived SVF cells are readily obtained from human lipoaspirate samples using enzymatic digestion to separate the SVF cells from the extracellular matrix and the adipocytes.  The stromal vascular fraction obtained from adipose tissue has been characterized by flow cytometry and contains a mesenchymal stem cell compartment (MSC) (6.7%), an endothelial precursor cell compartment (EPC) (2%) and a monocyte/macrophage compartment (10%) (Mitchell et al., 2006; Riordan, 2009; Varma et al., 2007). Differences in cytometric assessment result from use of different isolation techniques, different cell surface markers, and/or different gating strategies for the flow cytometer.  The SVF does not include any mature adipocytes (floating cells).  Only non-floating mono-nucleated cells are counted in the SVF and the counting method used to assay the SVF needs to be capable of accurately excluding RBC’s and other non-viable small debris fragments, RBCs, and oil droplets.  

In this paper we describe use of autologous adipose-derived SVF to treat OA in 11 knees of 6 patients (5 patients with bilateral OA and 1 patient with unilateral disease) with initial pain evaluated at 4 or greater on a 10 point scale.  Our objective with this pilot study was to evaluate the safety of SVF injection for OA of the knee as well as initial potential clinical changes resulting from injection of the SVF.  This clinical study was submitted for IRB review and approval (IntegReview, Austin, TX, USA).  The study is listed on the clinical trials.gov website, number NCT02357485. 

 
<< Start < Prev 21 22 23 24 25 26 27 28 29 30 Next > End >>

Page 26 of 40


Copyright © 2009-2018 ASERF. 11262 Monarch St., Garden Grove, CA 92841-1441 P: 800-364-2147 F: 562-799-1098